Prostacyclin Therapy for Pulmonary Arterial Hypertension: New Directions

ABSTRACT

Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and smooth muscle cell proliferation of the pulmonary arterioles, as well as in situ thrombosis of the small pulmonary arteries. Prostacyclin is involved in PAH vascular remodeling. It is unclear if decreased prostacyclin in the lungs is a cause or a consequence of PAH, but the relative lack of prostacyclin and its positive effects on the pulmonary vascular bed support the theory that long-term prostacyclin replacement is effective. Current therapies based on evidence-based medicine include epoprostenol, treprostinil, iloprost, and beraprost, each with limitations based on the drugs' inherent properties and administration route. Treatment of PAH by inhibiting multiple pathways concurrently may produce additive benefit. Because prostacyclin therapy is not curative and does not normalize pulmonary hemodynamics in the majority of cases, combining a prostacyclin with other PAH agents may be a promising approach.

KEYWORDS

Pulmonary arterial hypertension - prostacyclin - combination therapies

REFERENCES

• 1 Geraci M W, Gao B, Shepherd D C et al.. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension.  J Clin Invest. 1999;  103 1509-1515
• 2 Nagaya N, Yokoyama C, Kyotani S et al.. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats.  Circulation. 2000;  102 2005-2010
• 3 Tuder R, Cool C, Geraci M et al.. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.  Am J Respir Crit Care Med. 1999;  159 1925-1932
• 4 Zucker T P, Bonisch D, Hasse A, Grosser T, Weber A A, Schror K. Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells.  Eur J Pharmacol. 1998;  345 213-220
• 5 Christman B, McPherson C, Newman J et al.. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.  N Engl J Med. 1992;  327 70-75
• 6 Welsh C, Hassell K, Badesch D, Kressin D, Marlar R. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension.  Chest. 1996;  110 710-717
• 7 Moncada S, Vane J R. Prostacyclin: homeostatic regulator or biological curiosity?.  Clin Sci (Lond). 1981;  61 369-372
• 8 Miyamori I, Morise T, Yasuhara S, Takeda Y, Koshida H, Takeda R. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.  Br J Clin Pharmacol. 1985;  20 681-683
• 9 Cheng Y, Austin S C, Rocca B et al.. Role of prostacyclin in the cardiovascular response to thromboxane A2.  Science. 2002;  296 539-541
• 10 Oudiz R J, Schilz R J, Barst R J et al.. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.  Chest. 2004;  126 420-427
• 11 McLaughlin V, Genthner D, Panella M, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.  N Engl J Med. 1998;  338 273-277
• 12 Blumberg F, Riegger G, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise.  Chest. 2002;  121 1566-1571
• 13 Clapp L, Finney P, Turcato S, Tran S, Rubin L, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.  Am J Respir Cell Mol Biol. 2002;  26 194-201
• 14 Data J L, Molony B A, Meinzinger M M, Gorman R R. Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3′:5′-cyclic monophosphate levels.  Circulation. 1981;  64 4-12
• 15 Hyman A L, Kadowitz P J. Pulmonary vasodilator activity of prostacyclin (PGI₂) in the cat.  Circ Res. 1979;  45 404-409
• 16 Starling M B, Neutze J M, Elliott R L. Control of elevated pulmonary vascular resistance in neonatal swine with prostacyclin (PGI₂).  Prostaglandins Med. 1979;  3 105-117
• 17 Weir E K, Rubin L J, Ayres S M et al.. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.  Am Rev Respir Dis. 1989;  140 1623-1630
• 18 Rubin L J, Groves B M, Reeves J T, Frosolono M, Handel F, Cato A E. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.  Circulation. 1982;  66 334-338
• 19 Reeves J T, Groves B M, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension.  Am Rev Respir Dis. 1986;  134 342-346
• 20 Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).  Lancet. 1984;  1 1046-1047
• 21 Rubin L, Mendoza J, Hood M et al.. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol).  Ann Intern Med. 1990;  112 485-491
• 22 Nootens M, Schrader B, Kaufman E et al.. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension.  Chest. 1995;  107 54
• 23 Raffy O, Azarian R, Brenot F et al.. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension.  Circulation. 1996;  93 484
• 24 Krasuski R, Warner J, Wang A, Harrison J, Tapson V, Bashore T. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology.  J Am Coll Cardiol. 2000;  36 2204-2211
• 25 Ricciardi M, Knight B, Martinez F, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine.  J Am Coll Cardiol. 1998;  32 1068-1073
• 26 Barst R, Rubin L, Long W et al.. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.  N Engl J Med. 1996;  334 296-301
• 27 Sitbon O, Humbert M, Nunes H et al.. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.  J Am Coll Cardiol. 2002;  40 780-788
• 28 McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.  Circulation. 2002;  106 1477-1482
• 29 Badesch D, Tapson V, McGoon M et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease.  Ann Intern Med. 2000;  132 425-434
• 30 Kuhn K, Byrne D, Arbogast P G et al.. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.  Am J Respir Crit Care Med. 2003;  167 580-586
• 31 Humbert M, Sanchez O, Fartoukh M et al.. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.  Eur Respir J. 1999;  13 1351-1356
• 32 Rosenzweig E, Kerstein D, Barst R. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.  Circulation. 1999;  99 1858-1865
• 33 Tan H P, Markowitz J S, Montgomery R A et al.. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol.  Liver Transpl. 2001;  7 745-749
• 34 Plotkin J S, Kuo P C, Rubin L J et al.. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension.  Transplantation. 1998;  65 457-459
• 35 Nunes H, Humbert M, Sitbon O et al.. Prognositc factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2003;  167 1433-1439
• 36 Aguilar R, Farber H. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.  Am J Respir Crit Care Med. 2000;  162 1846-1850
• 36a Robbins I M, Chirstman B W, Newman J H et al.. A survey of diagnostic practices and the use of epoprostenal in patients with primary pulmonary hypertension.  Chest. 1998;  114 1269-1275
• 37 Rubin L J. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(Suppl 1) 4S-6S
• 38 Rubin L J. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(Suppl 1) 7S-10S
• 39 Badesch D B, Abman S H, Ahearn G S et al.. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(Suppl 1) 35S-62S
• 40 Wade M, Baker F J, Roscigno R, DellaMaestra W, Hunt T L, Lai A A. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.  J Clin Pharmacol. 2004;  44 83-88
• 41 Simonneau G, Barst R J, Galie N et al.. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
• 42 Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers.  J Cardiovasc Pharmacol. 2004;  44 209-214
• 43 Hoeper M, Schwarze M, Ehlerding S et al.. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.  N Engl J Med. 2000;  342 1866-1870
• 44 Gessler T, Schmehl T, Hoeper M M et al.. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension.  Eur Respir J. 2001;  17 14-19
• 45 Olschewski H, Simonneau G, Galie N et al.. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 46 Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease.  Am J Cardiol. 2003;  92 1007-1009
• 47 Opitz C F, Wensel R, Bettmann M et al.. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation.  Eur Heart J. 2003;  24 356-365
• 48 Galie N, Humbert M, Vachiery J-L et al.. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.  J Am Coll Cardiol. 2002;  39 1496-1502
• 49 Barst R, McGoon M, McLaughlin V et al.. Beraprost therapy for pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  41 2119-2125
• 50 Rubin L, Badesch D, Barst R et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 51 Humbert M, Barst R J, Robbins I M et al.. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.  Eur Respir J. 2004;  24 353-359
• 52 Hoeper M M, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.  Eur Respir J. 2003;  22 330-334
• 53 Itoh T, Nagaya N, Fujii T et al.. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats.  Am J Respir Crit Care Med. 2004;  169 34-38
• 54 Ghofrani H A, Rose F, Schermuly R T et al.. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  42 158-164
• 55 Stiebellehner L, Petkov V, Vonbank K et al.. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.  Chest. 2003;  123 1293-1295